Smitha S. Krishnamurthi, MD

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the IMPROVE trial, which she said showed significant results in terms of the length of PFS on treatment with an intermittent panitumumab plus FOLFIRI strategy.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the TRIPLETE trial, which she said showed no improvement when irinotecan was added to FOLFOX panitumumab in patients with mostly unresectable RAS and BRAF wild-type left-sided metastatic colorectal cancer.

In this video, Smitha S. Krishnamurthi, MD, discussed the results of the STRATEGIC-1 trial, which she said validates a common initial treatment strategy for patients with RAS and BRAF wild-type metastatic colorectal cancer.